TTR and neurodegenerative disease: Tafamidis reduces TTR amyloid and soluble misfolded TTR assemblies in FAP (Barroso et al., 2017; Coelho et al., 2012; Schonhoft et al., 2017), and remains the only therapeutic for a neurodegenerative disease that specifically targets the underlying causative amyloidogenesis.